Background: Bone marrow-derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury. Aims: To test the safety of G-CSF and define the exact dose capable of mobilizing BMSC in the majority of patients with liver cirrhosis; and to assess the feasibility of leukapheresis to collect BMSC from peripheral blood. Methods: In this study, we treated 18 patients affected by liver cirrhosis with increasing doses of G-CSF to mobilize CD34+ and CD133+ BMSC into the peripheral blood. Results: The dose-finding phase demonstrated that 15 μg/kg/day of G-CSF is the optimal dose to mobilize both CD34+ and CD133+ stem cells. Circulating BMSC were collected by a single step leukapheresis in three patients and the mean number of CD34+ and CD133+ cells cryopreserved was 1.3 ± 0.7 and 1.2 ± 0.5 × 106/kg, respectively. No severe adverse events were observed during the drug administration and stem cell collection. Noteworthy is, none of the patients showed a significant modification of liver function. Conclusions: Our study demonstrates that G-CSF administration and BMSC collection from the peripheral blood is possible and safe in patients with liver cirrhosis. The optimal dose to mobilize BMSC in cirrhotics is 15 μg/kg/day. At this dose, G-CSF does not seem to modify the residual liver function in cirrhotic patients

Stem cell mobilization and collection in patients with liver cirrhosis / Lorenzini, S; Isidori, Alessandro; Catani, Lucia; Gramenzi, Annagiulia; Talarico, S; Bonifazi, Francesca; Giudice, V; Conte, R; Baccarani, Michele; Bernardi, Mauro; Forbes, Sj; Lemoli, Roberto Massimo; Andreone, Pietro. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 27:10(2008), pp. 932-939. [10.1111/j.1365-2036.2008.03670.x]

Stem cell mobilization and collection in patients with liver cirrhosis

BERNARDI, MAURO;LEMOLI, ROBERTO MASSIMO;ANDREONE, PIETRO
2008

Abstract

Background: Bone marrow-derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury. Aims: To test the safety of G-CSF and define the exact dose capable of mobilizing BMSC in the majority of patients with liver cirrhosis; and to assess the feasibility of leukapheresis to collect BMSC from peripheral blood. Methods: In this study, we treated 18 patients affected by liver cirrhosis with increasing doses of G-CSF to mobilize CD34+ and CD133+ BMSC into the peripheral blood. Results: The dose-finding phase demonstrated that 15 μg/kg/day of G-CSF is the optimal dose to mobilize both CD34+ and CD133+ stem cells. Circulating BMSC were collected by a single step leukapheresis in three patients and the mean number of CD34+ and CD133+ cells cryopreserved was 1.3 ± 0.7 and 1.2 ± 0.5 × 106/kg, respectively. No severe adverse events were observed during the drug administration and stem cell collection. Noteworthy is, none of the patients showed a significant modification of liver function. Conclusions: Our study demonstrates that G-CSF administration and BMSC collection from the peripheral blood is possible and safe in patients with liver cirrhosis. The optimal dose to mobilize BMSC in cirrhotics is 15 μg/kg/day. At this dose, G-CSF does not seem to modify the residual liver function in cirrhotic patients
2008
27
10
932
939
Stem cell mobilization and collection in patients with liver cirrhosis / Lorenzini, S; Isidori, Alessandro; Catani, Lucia; Gramenzi, Annagiulia; Talarico, S; Bonifazi, Francesca; Giudice, V; Conte, R; Baccarani, Michele; Bernardi, Mauro; Forbes, Sj; Lemoli, Roberto Massimo; Andreone, Pietro. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 27:10(2008), pp. 932-939. [10.1111/j.1365-2036.2008.03670.x]
Lorenzini, S; Isidori, Alessandro; Catani, Lucia; Gramenzi, Annagiulia; Talarico, S; Bonifazi, Francesca; Giudice, V; Conte, R; Baccarani, Michele; Bernardi, Mauro; Forbes, Sj; Lemoli, Roberto Massimo; Andreone, Pietro
File in questo prodotto:
File Dimensione Formato  
G-CSF.pdf

Accesso riservato

Dimensione 171.29 kB
Formato Adobe PDF
171.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237140
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 45
social impact